3. Methods
This phase 3 multicenter, double-blind, randomized,
placebo-controlled trial was conducted at 119 sites in 9
countries
3
4. Tirzepatide is a once-weekly subcutaneous injectable
peptide engineered from the native GIP sequence, with
agonist activity at both the GIP and GLP-1 receptors.
The present trial, SURMOUNT-1, evaluated the efficacy and
safety of tirzepatide in adults with obesity or overweight who
did not have diabetes.
4
5. Participants
Key inclusion criteria:
1. adults who were 18 years of age or older
2. BMI of 30 ↑
3. BMI of 27 ↑ and at least one weight-related complication
(e.g., hypertension, dyslipidemia, obstructive sleep apnea,
or cardiovascular disease)
4. who reported one or more unsuccessful dietary effort to
lose weight were eligible to participate
5
6. Participants
Key exclusion criteria:
1. diabetes
2. a change in body weight of more than 5 kg within 90 days
before screening
3. previous or planned surgical treatment for obesity
4. treatment with a medication that promotes weight loss
within 90 days before screening
6
8. tirzepatide 5 mg, 10 mg, or 15 mg or placebo (1:1:1:1)
once weekly SC for 72 weeks with lifestyle intervention
a. regular lifestyle counseling sessions delivered by a
dietitian or a qualified health care professional
b. with a deficit of 500 calories/day ↓, and at least 150
minutes of physical activity/week
8
9. Participants
In 2539 participants, 86.0% completed the primary trial
treatment period and 81.9% adhered to the treatment or
placebo as assigned.
Treatment discontinuations due to adverse events
9
5 mg 10 mg 15 mg placebo
4.3% 7.1% 6.2% 2.6%
24. Coprimary End Points- Change in Body Weight
24
This is an unusually substantial degree of weight reduction
in response to an antiobesity medication as compared with
findings reported in other phase 3 clinical trials.
26. CONCLUSIONS
All three doses of once-weekly subcutaneous tirzepatide led
to clinically meaningful and sustained weight reduction in
obese adults who did not have diabetes.
Only 5.5% of trial participants with overweight (BMI of 27 to
<30) were included; further studies would be needed in such
patients.
26
Editor's Notes
目前的試驗SURMOUNT-1評估了替西帕肽對沒有糖尿病的肥胖或超重成人的有效性和安全性。
第一个也是唯一一个获得 FDA 批准的 GIP 和 GLP-1 受体激动剂。(approved by FDA for type 2 diabetes)
有三組參與者在72週內,每週注射不同劑量的替西帕肽,三組人體重都有明顯的改善,其中使用最高劑量的參與者平均減輕20%的體重